Published in Hum Hered on June 10, 2010
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A (2009) 54.68
Genome-wide association studies for common diseases and complex traits. Nat Rev Genet (2005) 33.96
Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol (1995) 30.55
A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet (2006) 28.32
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet (2003) 21.52
Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics (1992) 21.26
A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 18.98
Pancreatic cancer. Lancet (2004) 11.63
Inheritance and drug response. N Engl J Med (2003) 5.78
Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. Am J Hum Genet (2008) 3.86
Genetic association studies. Lancet (2005) 3.35
A Bayesian toolkit for genetic association studies. Genet Epidemiol (2006) 2.86
Hierarchical modeling of linkage disequilibrium: genetic structure and spatial relations. Am J Hum Genet (2003) 2.05
Variable selection and Bayesian model averaging in case-control studies. Stat Med (2001) 1.91
Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet (2006) 1.76
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Bayesian modeling of complex metabolic pathways. Hum Hered (2003) 1.60
Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet (2006) 1.50
Genetic analysis with hierarchical models. Genet Epidemiol (1997) 1.28
Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol (2004) 1.09
A hidden Markov random field model for genome-wide association studies. Biostatistics (2009) 1.05
The art and science of personalized medicine. Clin Pharmacol Ther (2007) 1.05
The application of genetics to the discovery of better medicines. Pharmacogenomics (2002) 0.80
Missing phenotype data imputation in pedigree data analysis. Genet Epidemiol (2008) 0.79
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res (2010) 1.87
Self-contained gene-set analysis of expression data: an evaluation of existing and novel methods. PLoS One (2010) 1.67
Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. Am J Hum Genet (2006) 1.50
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res (2010) 1.37
Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet (2006) 1.37
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics (2012) 1.34
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res (2011) 1.32
Completion pneumonectomy: factors affecting operative mortality and cardiopulmonary morbidity. Ann Thorac Surg (2002) 1.20
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12
Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study. Toxicol Sci (2010) 1.11
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genet Epidemiol (2011) 1.06
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol (2013) 1.02
Use of the gamma method for self-contained gene-set analysis of SNP data. Eur J Hum Genet (2011) 1.01
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol (2014) 0.94
Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr Pract (2007) 0.91
FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics (2013) 0.90
Genome-wide gene-set analysis for identification of pathways associated with alcohol dependence. Int J Neuropsychopharmacol (2012) 0.89
Serine hydroxymethyltransferase 1 and 2: gene sequence variation and functional genomic characterization. J Neurochem (2012) 0.88
Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenet Genomics (2009) 0.87
Incidence and clinical spectrum of thiazide-associated hypercalcemia. Am J Med (2007) 0.87
A latent model for prioritization of SNPs for functional studies. PLoS One (2011) 0.86
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics (2011) 0.86
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. Cancer Epidemiol Biomarkers Prev (2012) 0.85
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics (2012) 0.83
Soft truncation thresholding for gene set analysis of RNA-seq data: application to a vaccine study. Sci Rep (2013) 0.83
Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen. Int Immunopharmacol (2011) 0.83
Localization of association signal from risk and protective variants in sequencing studies. Front Genet (2012) 0.82
Human liver methionine cycle: MAT1A and GNMT gene resequencing, functional genomics, and hepatic genotype-phenotype correlation. Drug Metab Dispos (2012) 0.81
A Bayesian integrative genomic model for pathway analysis of complex traits. Genet Epidemiol (2012) 0.81
Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos (2010) 0.81
Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care (2005) 0.81
Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG. PLoS One (2012) 0.79
Integrative gene set analysis: application to platinum pharmacogenomics. OMICS (2013) 0.78
Regression modeling of allele frequencies and testing Hardy Weinberg Equilibrium. Hum Hered (2013) 0.78
Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies. Genet Epidemiol (2013) 0.77
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One (2013) 0.76